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Background: The evidence for choices between antipsychotics for children and adolescents with schizophrenia
and other psychotic disorders is limited. The main objective of the Tolerability and Efficacy of Antipsychotics (TEA)
trial is to compare the benefits and harms of quetiapine versus aripiprazole in children and adolescents with
psychosis in order to inform rational, effective and safe treatment selections.
Methods/Design: The TEA trial is a Danish investigator-initiated, independently funded, multi-centre, randomised,
blinded clinical trial. Based on sample size estimation, 112 patients aged 12-17 years with psychosis, antipsychotic-naïve
or treated for a limited period are, 1:1 randomised to a 12- week, double-blind intervention with quetiapine versus
aripiprazole. Effects on psychopathology, cognition, health-related quality of life, and adverse events are assessed
2, 4, and 12 weeks after randomisation. The primary outcome is change in the positive symptom score of the Positive
and Negative Syndrome Scale. The recruitment period is 2010-2014.
Discussion: Antipsychotics are currently the only available pharmacologic treatments for psychotic disorders. However,
information about head-to-head differences in efficacy and tolerability of antipsychotics are scarce in children and
adolescents. The TEA trial aims at expanding the evidence base for the use of antipsychotics in early onset psychosis in
order to inform more rational treatment decisions in this vulnerable population. Here, we account for the trial design,
address methodological challenges, and discuss the estimation of sample size.
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Early onset psychosis (EOP, onset before age 18 years) is
considered grave and may have worse outcomes compared
to adult onset psychosis [1,2]. In adults, antipsychotics
have proven more effective than placebo in improving
psychotic symptoms and preventing relapse [3,4] and
comparisons of benefits and harms of different anti-
psychotic drugs have been assessed in large meta-analyses
[5,6]. In children and adolescents with EOP, placebo-
controlled trials and, especially, active-controlled trials
are limited [7-10].
Seven primarily industry-sponsored randomised placebo-
controlled trials covering a total of 1198 children and
adolescents with schizophrenia have been published:
six trials investigated effects of the second-generation
antipsychotics (SGAs) aripiprazole [11], olanzapine [12],
risperidone [13], paliperidone [14], quetiapine [15], and
ziprasidone [16] in adolescents with schizophrenia. One
trial compared the first-generation antipsychotic (FGA)
haloperidol with placebo in children with schizophrenia
[17]. Six of these seven trials showed superiority of the
antipsychotic compared with placebo. The ziprasidone
trial was terminated due to lack of efficacy. Only 12
randomised clinical trials (RCTs) compared different
antipsychotics in the treatment of EOP. Five RCTs were
open-label head-to-head studies investigating olanzapine
versus (vs) risperidone (n = 44, including adolescents
and young adults aged 16-28 years) [18]; risperidone vs
olanzapine vs quetiapine (n = 30) [19]; olanzapine vs
quetiapine (n = 50) [20]; quetiapine vs risperidone (n = 22)
[21]; and olanzapine vs risperidone (n = 25) [22]. Six
RCTs were double-blind, head-to-head trials investigating
clozapine vs haloperidol (n = 21) [23]; clozapine vs olanza-
pine (n = 39) [24]; clozapine vs olanzapine (n = 25) [25];
risperidone vs olanzapine vs haloperidol (n = 50, including
both non-affective and affective psychotic disorders)
[26]; olanzapine vs risperidone vs molindone (n = 119)
[27]; and a double-blind RCT (n = 126) comparing pali-
peridone vs aripiprazole [28]. One older RCT assessed
thiothixene vs thioridazine (n = 21) [29]. Across these
trials, only clozapine has shown superiority compared
with other antipsychotics (haloperidol or olanzapine) when
used for treatment-resistant early onset schizophrenia
[23-25]. Each of these head-to-head RCTs included
small to medium size patient samples (total n = 572). In
comparison, a recent meta-analysis of antipsychotic
drugs in adult schizophrenia included data from 43,049
patients [6]. It is problematic that the use of antipsychotics
in EOP to a large extent is based on extrapolations from
trials conducted in adults, considering that the prevalence
of adverse reactions and treatment resistance may be
higher in children and adolescents [20,30-32].
Outcome of antipsychotic treatment in psychosis is
typically assessed with validated psychopathology scalesand unsolicited adverse effect reporting, supplemented
with usually few validated adverse events scales and some
physical health parameters. However, other potential
outcomes are also relevant for the prognosis of EOP,
including cognitive deficits [33-41] and health-related
quality of life (HRQoL) [42]. It has been difficult to
observe consistent effects of antipsychotics on these
outcomes in adults [38,39,43-45], and in the few studies
conducted in EOP [46-50].
The Food and Drug Administration (FDA) has approved
the use of quetiapine and aripiprazole in the treatment
of schizophrenia from age 13 years, but no trials have
compared the two drugs in EOP [51]. Here, we present
the trial protocol of an investigator-initiated and inde-
pendently funded RCT comparing the effects of quetiapine
vs aripiprazole in EOP.Objectives
The primary objective of the TEA (Tolerability and Efficacy
of Antipsychotics) trial is to compare quetiapine vs ari-
piprazole in the treatment of EOP with regards to efficacy
(psychopathology, cognition, HRQoL) and tolerability
(motor adverse events (AEs); metabolic AEs; hormonal
AEs; cardiac AEs, suicidal ideation; and other AEs) in
a randomised, blinded design.Hypotheses
The TEA trial tests the null hypothesis that there are no
significant differences between quetiapine vs aripiprazole in
EOP after 12 weeks of treatment on the primary outcome,
Positive and Negative Syndrome Scale (PANSS) positive
symptoms (PANSS-P) [52]. Due to different receptor pro-
files and prior data [7,8,11,15] we expect specific differences
in secondary outcomes primarily reflected in adverse effect
assessments with aripiprazole causing more akathisia than
quetiapine; and quetiapine causing more sedation, weight
gain, and metabolic adverse effects than aripiprazole.Methods/Design
RCT design
The TEA trial is a Danish investigator-initiated, independ-
ently funded, randomised, blinded, multi-centre superiority
trial. Patients (n = 112) are randomised to a 12 weeks inter-
vention period with quetiapine vs aripiprazole.Participants
Patients are recruited from seven child- and adolescent
mental health centres covering all Danish university clinics
nationwide (University Hospitals of Copenhagen (4 centres),
Southern Denmark (1 centre), Aarhus (1 centre), and
Aalborg (1 centre)).
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Inclusion criteria: 1) Children and adolescents aged
12-17 years (both inclusive), both sexes; 2) in- or
outpatients; 3) meeting the criteria for ICD-10 [53]
psychosis diagnoses (non-organic, non-drug-induced):
F20 (Schizophrenia), F22 (Persistent delusional disorders),
F23 (Acute and transient psychotic disorders), F24
(Induced delusional disorders), F25 (Schizoaffective disor-
ders), F28/F29 (Other/Unspecified nonorganic psychosis),
F30.2 (Mania with psychotic symptoms), F31.2 (Bipolar
affective disorder, current episode manic with psychotic
symptoms), F31.5 (Bipolar affective disorder, current
episode severe depression with psychotic symptoms), F32.3
(Severe depressive episode with psychotic symptoms), or
F33.3 (Recurrent depressive episode, current episode severe
with psychotic symptoms). The diagnosis is verified by
Schedule for Affective Disorders and Schizophrenia
for School-Age Children Present and Lifetime version
(K-SADS-PL) 4 weeks after inclusion into the trial
[54]; 4) clinical indication for antipsychotic treatment;
5) presence of psychotic symptoms scoring ≥4 on at
least one of the following PANSS items: P1 (delusions),
P2 (conceptual disorganisation), P3 (hallucinations), P5
(grandiosity), P6 (suspiciousness/persecution), or G9
(unusual thought content); as well as a total PANSS
score >60 points; 6) antipsychotic-naïve or limited expos-
ure (i.e., no more than 12 months in the past year for
psychosis, or no more than 1 week lifetime for any
non-psychotic indication); and 7) written informed
consent by caretakers.
Patient exclusion criteria
Exclusion criteria: 1) Compulsory treatment; 2) drug-
induced or organic psychosis; 3) severe chronic somatic
illness or a history of severe head trauma; 4) pregnancy
or lactation; 5) substance dependence (ICD-10 F1X.2
dependence syndrome) within the last year; 6) allergy
towards the investigational drugs or lactose intolerance;
7) lack of informed consent.
Randomisation and blinding
Randomisation of patients to treatment is carried out
centrally by the Copenhagen Trial Unit at the Capital
Region Pharmacy using a computer-generated allocation
sequence with a block size unknown to the investigators.
To optimise the comparability between treatment groups,
randomisation is stratified by two factors: PANSS-P score
(i.e., ≤20 points or >20 points), and age (i.e., 12-14 years
or 15-17 years). Computer-generated and sealed allocation
sequence lists are prepared according to the stratification
variables and the trial medication packages are distributed
accordingly. The interventions are blinded to participants,
caregivers, outcome assessors, statisticians, conclusion
drawers, as well as all investigators and staff involved inthe trial, except for the pharmacy personnel who pack and
distribute the two study drugs and the data managers at
the Copenhagen Trial Unit.
Interventions and assessments
During the first 9 days, the assigned antipsychotic is
uptitrated in fixed dose steps, with slower titrations and
dose adjustments if clinically indicated (see below). The
target doses are quetiapine 600 mg/day vs aripiprazole
20 mg/day. However, if needed, dosing is flexible (que-
tiapine: 50-800 mg/day; aripiprazole 2.5-30 mg/day).
Beneficial and harmful effects are assessed at three time
points during the intervention period, i.e., weeks 2, 4,
and 12.
Post-randomisation exclusions
Patients are excluded if there is a significant worsening
of their clinical state during the course of the trial (i.e.,
increases of 20% or more from baseline on the PANSS
total score).
Outcomes
The primary outcome is positive symptoms measured
on the PANSS-P scale. Secondary outcomes are 1) other
psychopathology measures assessed on PANSS negative
and general scales; Dimensions of Psychosis Instrument
(DIPI) [55]; Clinical Global Impressions - Severity/Im-
provement/Efficacy (CGI-S/I/E) [56]; Global Assessment
of Psychosocial Disability (GAPD) [53]); 2) cognition and
cognitive daily functioning measured on Brief Assessment
of Cognition in Schizophrenia (BACS) Global Score [57];
Schizophrenia Cognition Rating Scale, Danish version
(SCoRS-DK) [58]; Behavioural Rating Inventory of Execu-
tive Functions (BRIEF) [59]); 3) HRQoL measured on
KIDSCREEN-52 [60]; 4) adverse reactions measured on
‘Udvalget for Kliniske Undersøgelser’ Side Effect Rating
Scale (UKU) [61]; Abnormal Involuntary Movement
Scale (AIMS) [62]; Simpson Angus Scale (SAS) [63];
Barnes Akathisia Rating Scale (BARS) [64]; cardiac adverse
reactions (such as QT-interval prolongation on Electrocar-
diography (ECG)); somatic events (blood pressure, pulse,
body weight, height, body mass index, abdominal circum-
ference, abnormal laboratory test results (fasting blood
glucose, insulin and lipid levels, prolactin, other general
blood tests)); suicidal ideation measured by K-SADS-PL
(specific items); adherence (daily registration by caretakers
or staff and antipsychotic blood levels); substance use
(interview and urine testing) (Table 1).
Antipsychotic drugs
Quetiapine and aripiprazole
Quetiapine is a low-affinity dopamine D2 receptor
antagonist [65]. Aripiprazole has a high affinity for
dopamine D2 receptors but with a partial agonist









Psychopathology and adverse reactions rating scales PANSS,
DIPI, CGI-S, CGI-I, CGI-E, GAPD, UKU, AIMS, SAS, and BARS
X X X X
Suicidal ideation K-SADS-PL specific items X X X X
Cognition, cognitive daily and executive function BACS, SCoRS-DK and BRIEF X X
Somatic examination Standard clinical examination, blood pressure,
pulse, weight, height, BMI, and abdominal circumference.
X X X X
Health-related quality of life Questionnaire: KIDSCREEN-52 X X
Laboratory tests (see list below) X X X
AIMS = Abnormal Involuntary Movement Scale; BACS = Brief Assessment of Cognition in Schizophrenia; BARS = Barnes Akathisia Rating Scale; BMI = Body Mass
Index; BRIEF = Behavioural Rating Inventory of Executive Functions; CGI = Clinical Global Impression (-I = Improvement -S = Severity -E = Efficacy); DIPI = Dimensions
of Psychosis Instrument; GAPD = Global Assessment of Psychosocial Disability; HRQoL = Health related quality of life; K-SADS-PL = Kiddie-SADS-Present and Lifetime
Version; KIDSCREEN-52 = Health related quality of life questionnaire for children and young people and their parents; PANSS = Positive and Negative Syndrome
Scale; SCoRS-DK = Schizophrenia Cognition Rating Scale – Danish version; UKU = ‘Udvalget for Kliniske Undersøgelser’ Side Effect Rating Scale.
Laboratory tests: Blood tests (fasting): triglycerides; total cholesterol; high-density and low-density lipoproteins; glucose; insulin; prolactin; creatinphosphokinase;
haemoglobin; leukocyte cell and differential count; thrombocyte cell count; sodium; potassium; creatinine; aspartate amino transferase; alkaline phosphatases; thyroid
stimulating hormone; vitamin D; omega 3 fatty acids; genetic material (DNA). Blood samples to analyse serum values of antipsychotics are drawn at week 4 and 12, and
saved for later analysis. Urine tests: pregnancy test (at baseline and at follow-up if suspicion of pregnancy), screening for medication and substance abuse (at baseline
and at follow-up if suspicion of substance use). ECG: Standard leads.
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are approved by FDA and the European Medicines
Agency (EMA) for the treatment of schizophrenia in
adults. Aripiprazole is approved by the FDA for use in
schizophrenia for ages 13-17 years, and in Denmark
and the rest of the EU it has obtained authorisation
for use in adolescent schizophrenia for ages of 15-17
years by the EMA [67]. Quetiapine has FDA approval
for the treatment of schizophrenia for ages 13-17
years, but it has not been approved by EMA for use
below age 18 years. In the present trial, quetiapine and
aripiprazole were selected since these compounds are
frequently used in clinical child and adolescent psychi-
atric practice, and because it remains unclear whether
their different receptor binding profiles can be related
to differences in clinical outcomes in EOP. In adults, a
recent Cochrane systematic review found no significant
differences between quetiapine vs aripiprazole (global
state (n = 991, 12 RCTs); PANSS-P (n = 583, 7 RCTs);
leaving the study early for any reason (n = 168, 2 RCTs),
or general extra pyramidal symptoms (n = 348, 4 RCTs);
all low to very low quality evidence). Results were sig-
nificantly in favor of aripiprazole regarding Quality of
Life (n = 100, 1 RCT, mean difference 2.60, 95% CI 1.31
to 3.89), however, evidence was rated very low quality
[51]. Notably, all studies were conducted in China and
in adult Chinese patients. Currently, no single Western
RCT has compared quetiapine with aripiprazole either
in adults or in children and adolescents.
Quetiapine and quetiapine extended release
Studies have shown that quetiapine 200-800 mg/day
improves psychotic symptoms in patients with EOP
(age 11-17 years) [68], and 300-800 mg/day showedacceptable long-term (88 weeks) safety and tolerability
(n = 10, age 12-16 years [69]). Patients aged 10–17 years
(n = 27) tolerated quetiapine doses of 400 mg twice
daily, with no serious AEs and no unexpected events re-
ported, and compared to a parallel adult population there
were similar pharmacokinetic, safety, and tolerability pro-
files by dose escalation, suggesting that no dosage adjust-
ment is required when treating patients of these ages [70].
One 6-week, double-blind, placebo-controlled RCT of
quetiapine 400 or 800 mg/day in 220 adolescents with
schizophrenia aged 13-17 years found significant improve-
ments in PANSS total score changes at both quetiapine
doses compared with placebo, and quetiapine was gener-
ally well tolerated with a profile broadly similar to that
reported in adult populations [15]. A 12-week open label
study of quetiapine in 56 adolescents with schizophrenia
spectrum disorder found a significant reduction of PANSS
total and particularly positive symptom scores [71]. It is
generally assumed that younger patients require lower
doses of antipsychotics than adults. However, for quetia-
pine this may be true for younger children with lower
body weight, but adolescents typically require rapid
titration to the same, or even higher, dose levels than
adults for optimal clinical response [32]. Higher doses
of quetiapine than those recommended by the compound
producer have proven to be effective and safe in adolescents
[26]. Extended release quetiapine allows a once-daily dosing
and has been proven effective and well tolerated in adults
with schizophrenia in a randomised, placebo-controlled
trial [72]. This formulation will be used in the present trial
in order to match the once a day dosing of aripiprazole.
We use a 9-day fixed titration phase with a final que-
tiapine extended release dose of 600 mg/day (Table 2). If
needed for efficacy, the possible maximum dose can be
Table 2 Schedule of dosing regimen
Level 1 2 3 4 5* 6**
Day 1 2 3 4 5 6 7 8 9 …
Quetiapine ER (mg) 50 50 100 100 200 200 400 400 600 800
Aripiprazole (mg) 2.5 2.5 5 5 10 10 15 15 20 30
Number of capsules 1 1 2 2 1 1 2 2 3 4
Quetiapine ER: ● ● ●● ●● ● ● ●● ●● ●●● ●●●●
Aripiprazole: ● ● ●○ ●○ ● ● ●○ ●○ ●●○ ●●○○
Due to unparalleled strengths in formulations of quetiapine ER and aripiprazole, the use of capsules filled with a neutral ingredient (lactose) is needed in order to
have the same number of capsules for each compound at each level. ER=extended release.
*Level 5 = final level; **Level 6 = maximal level (if needed);
●Capsules with active compound; ○ Capsules without active compound.
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dose level if not tolerated (minimum 50 mg/day).
Aripiprazole
The safety of aripiprazole used in children and adolescents
from the age of 7 years has mainly been documented in
open-label or naturalistic studies of disorders other than
psychosis, i.e., Tourette’s syndrome or developmental dis-
orders, using doses in the mean range of 5-17 mg/day
[73-78]. A double-blinded multi-centre RCT compared
aripiprazole 10 mg/day and 30 mg/day with placebo in
302 adolescents (aged 13-17 years) with schizophrenia
[11]. The trial authors concluded that 6 weeks treatment
with aripiprazole was generally well tolerated and lead
to significant improvements in psychotic symptoms
compared with placebo. An open-label trial with 21
patients aged 10-17 with bipolar or schizophrenia spec-
trum disorders compared daily doses of 20, 25 or 30 mg
aripiprazole in a 12-days titration phase, followed by a
14-days fixed dose phase. Effectiveness and criteria for
tolerability were met for all doses, and no adverse
reactions met the regulatory criteria for serious adverse
reactions [79].
We use a 9-day fixed titration phase with a final aripi-
prazole dose of 20 mg/day (Table 2). If needed for efficacy,
the possible maximum dose can be titrated up to 30 mg/
day. If final doses are not tolerated, patients can be titrated
down to a lower dose level (minimum 2.5 mg/day).
Concomitant medications
Patients will not be allowed any concomitant antipsychotic
medication before all trial assessments at week 12 have
been conducted. Concomitant medication of any kind
beyond trial medications will be recorded throughout
the trial intervention period.
Sample size estimation
The sample size estimation is based on the primary out-
come measure, the PANSS-P score. In 2009, when the
TEA trial was designed, the estimated standard deviation
(SD) for PANSS-P was based on the few studies that upuntil then had investigated efficacy of the trial drugs
(quetiapine or aripiprazole) in patients below 18 years of
age with psychosis [11,20,71]. The three studies reported
mean PANSS-P in patients treated with quetiapine or
aripiprazole with SDs ranging from 4.1 to 7.4, or stand-
ard error (SE) for change of PANSS-P from entry to end
of treatment of around 0.6 (corresponding to SD = 5.9).
Furthermore, in our previous case-control study of pa-
tients comparable to the TEA participants, consisting of
Danish minimally medicated children and adolescents
with psychosis aged 12-18 years, the SD of PANSS-P at
the time of first-episode psychosis was within the above
range, SD = 5.1 [80,81]. Consequently, we used a conser-
vative estimate of the (at that time) highest reported SD
of 7.4 in the original sample size estimation. Since then,
however, more studies on aripiprazole and quetiapine in
early onset psychosis point toward lower SDs on the
PANSS-P ranging from 4.3 to 6.3 [15,21,28] (see all rele-
vant studies in Table 3). A weighted mean SD of PANSS-P
based on data from all 6 studies in Table 3 equals 5.48 for
all SDs, and 5.68 for SDs of change scores. Hence, based
on the entirety of the available data, we updated our
sample size calculation based on a SD of 5.7 on the
PANSS-P scale.
Based on results from a 24 weeks RCT comparing
olanzapine with quetiapine that found a mean difference
in PANNS-P scores of 4 points in favour of olanzapine
(a difference that did not reach significance probably
due to the small group size of 25 patients each) [20],
we decided that a minimal clinically relevant difference
between outcome responses of quetiapine vs aripiprazole
after (the shorter period of) 12 weeks of treatment would
be 3 points on the PANSS-P. Hence, using a power of
80% and a two-sided alpha of 5%, and expecting a SD of
5.7 on the PANSS-P, the required sample size necessary
to detect or reject a difference of at least 3 points on
PANSS-P was estimated as follows (N = total sample size,
SD of the primary outcome measure = 5.7 (we assume
SD1 = SD2), α = type 1 error = 0.05, β = type 2 error = 0.20,
MIREDIF = minimal relevant difference of outcome
measure = 3, z = fractiles in normal distribution): N= 2 *
Table 3 Data from trials on quetiapine or aripiprazole in patients below 19 years with psychosis used for final power calculation
Study (reference) Design and
population




Change PANSS-P scores from
baseline to follow-up (SD)
Schimmelman et al. 2007 [71] Open Label Quetiapine N=52 Quetiapine: Quetiapine: Quetiapine:
Non-RCT




Findling et al. 2008 [11] Double-blind RCT
6 weeks
Aripiprazole 10 mg/





Aripiprazole 10 mg: 14.5
(SE=0.6 i.e. SD=6.0*)






Aripiprazole 20 mg: 15.4
(SE=0.6 i.e. SD=5.9*)
Aripiprazole 20 mg: -8.1
(SE=0.6 i.e. SD=5.9*)
Arango et al. 2009 [20] Open label RCT Quetiapine vs Olanzapine N=50 Quetiapine: Quetiapine: Quetiapine:
6 months (24 vs 26) 23.3 (7.3) 15.1 (4.1) -8.2 (na)
Psychotic disorders
Most drug-naïve flexible doses
12-18 years
Swadi et al. 2010 [21] Open label RCT Quetiapine up to 800 mg
vs risperidone up to 6 mg
N=22 na na Quetiapine:




Findling et al. 2012 [15] Double-blind RCT Quetiapine 400 mg/
800 mg vs placebo
N=220
(73 vs 74 vs 73)
Quetiapine 400 mg: 23.3 (5.8)
Quetiapine 800 mg: 23.8 (4.8)
na Quetiapine 400 mg:
6 weeks
Schiz.
-8.6 (SE 0.7, i.e. SD=6.3*)
13-17 years Quetiapine 800 mg:
-9.3 (SE 0.6, i.e. SD=5.1*)
NCT01009047 2013 [28] Double-blind RCT Paliperidone ER 3-9 mg
vs Aripiprazole 5-15 mg
N=226 (112 vs 114) Aripiprazole: 22.5 (4.3) na Aripiprazole week 8:
8 weeks/26 weeks -6.2 (4.9)
Schiz. Aripiprazole week 26:
12-17 years -8.3 (6.1)
Data on PANSS positive scores and standard deviations from these studies were considered in the sample size estimation of the TEA study. Weighted average of all SDs=5.48 and of change in SD=5.68. ITT=Intention-
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2 + SD2
2) * (zα/2 + zβ)/MIREDIF
2 = 112. Accordingly, we
should strive to include a total of 112 patients, equivalent
to about 56 patients in each of the intervention groups.
Data analysis
Data will be blinded during the analysis, and the blinding
will not be broken before two conclusions are drawn
(i.e., the first assumes treatment A to be quetiapine
and treatment B to be the aripiprazole; the second is
based on the reverse assumption, i.e., that treatment A
is aripiprazole and B is quetiapine) [82]. A detailed
protocol for the statistical analysis plan will be presented
in a separate paper. In short, the primary analysis will be
according to the modified intention-to-treat principle [83]
with adjustment for the protocol specified stratification
variables [84]. Data missingness will be investigated and
if deemed necessary, generally when missingness is not
completely at random, a suitable multiple imputation
method will be used [85-92]. The data will be analysed
with a two-sided statistical testing and p-values will be
assessed at a significance level of 5% with correction for
multiple testing according to Holm [93]. Covariates
considered relevant to adjust for in comparative analysis
will be incorporated in the statistical model. We aim
at analysing the data as trajectories including multiple
assessments whenever possible.
Ethical considerations
As the trial is investigating medicinal products and the
participants are under 18 years of age, a surrogate written
informed consent is required from the holders of custody.
The trial is registered at ClinicalTrials.gov: NCT01119014,
EudraCT: 2009-016715-38, and approved by Danish
Medicines Agency: 2612-4168, The Ethics Committee of
Capital Region: H-3-2009-123 and Danish Data Protec-
tion Agency: 2009-41-3991. All procedures for register-
ing and reporting adverse reactions and adverse events
will follow the regulations and guidelines from the Danish
Health and Medicines Authority and the Ethics Committee.Discussion
Legitimacy of the trial
The use of antipsychotics in children and adolescents is
rising in many countries [94-97]. In Denmark, the number
of persons aged 0-18 years treated with antipsychotics
(all indications) increased by a factor four from 1999 to
2012 [98]. Secondly, off-label use is prevalent. In the
United States, five newer antipsychotics (aripiprazole,
olanzapine, paliperidone, quetiapine, and risperidone)
are currently approved for schizophrenia in children
aged 13 to 17, but in the EU until recently only one
compound (aripiprazole) has been approved for the use
in schizophrenia from age 15 (in June 2014 paliperidonewas approved for the same indication [99]). The off-label
use in paediatric populations is of major concern to the
EMA which calls for randomised trials [100]. Thirdly, in
child- and adolescent psychiatry only seven double-
blinded RCTs comparing antipsychotics for the treat-
ment of child- and adolescent psychosis have been
carried out, and since the clinical effects vary between
compounds and among patients, there is no doubt that
RCTs including large samples are lacking in this field.
Specifically, to date no RCTs investigated quetiapine vs
aripiprazole in EOP. Notably, even in adults, no RCT
outside of China has compared quetiapine vs aripiprazole
for the treatment of psychosis either [51]. Moreover, more
frequent and severe adverse effects that can have potential
long-term consequences, i.e., metabolic syndrome, may be
expected in young patients [8,101].
Time frame
A challenge in clinical practice and in trials is to identify
the relevant time frame for assessing the effectiveness of
antipsychotic treatment. We decided to investigate as
our primary outcome the antipsychotic response after
12 weeks of treatment. In clinical practice, the usual
routine is to continue treatment with an antipsychotic
drug for a period of at least 4 - 6 weeks to evaluate the
antipsychotic response. This individual drug trial period
is partly arbitrarily defined [102-105] based on older
preclinical studies [106]. However, brain imaging studies
of both FGAs and SGAs have shown that dopamine D2
receptor occupancy occurs within hours after adminis-
tration [107,108], and clinical antipsychotic effects can
be distinguished from non-specific sedative effects within
the first 24 hours of treatment [104]. Studies in adults
have demonstrated that the largest effect of antipsychotics
occur during the first four weeks of treatment [103,109],
and that the early response after 4 weeks can predict
long-term effects [105]. The only two studies on this
issue in EOP found that early response to aripiprazole
after 3 weeks predicted well ultimate response at 6 weeks
in an RCT including youth with schizophrenia [51,110,111]
and that early response to mixed SGAs after 4 weeks pre-
dicted response at week 12 in naturalistically treated youth
with schizophrenia spectrum disorders [112]. In order to
further investigate the early clinical response as a predictor
of later clinically significant effects on psychopathology, we
decided to measure treatment responses after 2, 4 and
12 weeks of treatment in the randomised, blinded design,
and to measure the long-term effects in a naturalistic
design with follow-up at 1 year after randomisation.
Sample size estimation
The key consideration in designing a RCT is to know
the size of a sample needed to obtain limited probability
of type 1 (false positive) and type 2 (false negative) errors.
Pagsberg et al. BMC Psychiatry 2014, 14:199 Page 8 of 13
http://www.biomedcentral.com/1471-244X/14/199The sample size estimation is based on choices regarding
an acceptable risk of type 1 and 2 errors, on assumptions
regarding the variation in outcome measures, and finally
on the estimation of the minimal relevant difference in
clinical effect between the interventions under the trial.
Thus, the following four variables were considered:
1) α or type 1 error (the probability of rejecting the
null hypothesis when it is actually true) is usually set
at 0.05 two-sided. If we find a difference below this
level we may declare a significant difference, knowing
that there will still be a 5% risk that the null hypothesis
of no difference is correct.
2) We decided in our updated sample size estimation
to use a value of 80% for power, which is standard
and translates into accepting a 20% risk that we will
miss a true difference of the anticipated magnitude
between the two compounds of (in this case) 3
points on the PANSS-P scale.
3) The expected variation in the primary outcome
measure PANSS-P was initially driven by the only
three relevant RCTs (upper three studies in Table 3)
that were available in 2009 [11,20,71]. During our
recruitment in the TEA trial, more informative
studies have appeared (lower three studies in
Table 3), i.e., two published RCTs [15,21] and one
RCT reported to clinicaltrials.gov [28]. Based on a
weighted mean SD of change in PANSS-P scores
from all six trials, we used in our updated sample
size calculation a SD of 5.7 on the PANSS-P scale.
4) MIREDIF should represent a meaningful minimal
difference in response in the sense that it would
justify a choice between two interventions in a
clinical setting. The PANSS-P scale scores range
from 7 to 49, and the few relevant RCTs already
conducted found that the mean PANSS-P score
after 6 weeks to 6 months of treatment is around
15 in the aripiprazole or quetiapine groups with aTable 4 Sample size estimation
β SD MIREDIF
TEA original 0.10 7.4 3.5
TEA smaller MIREDIF 0.10 7.4 2.0
TEA larger MIREDIF 0.10 7.4 5.0
TEA larger SD 0.10 10.0 3.5
TEA smaller SD 0.10 5.7 3.5
TEA larger β 0.20 7.4 3.5
TEA updated larger β, smaller SD, smaller MIREDIF 0.20 5.7 3.0
The original and the updated TEA calculations and examples of different values of M
type II error) are shown. As can be seen, the larger the MIREDIF you wish/expect to
the larger the β, the smaller the sample size needed. In these calculations we used
sizes depend on MIREDIF and SD. Compared to the original calculation, the update
zsmaller SD and lowering the detectable MIREDIF. z = fractiles in normal distribution. #
The product 4 * (zα/2 + zβ)
2 is rounded up to whole figures in the equations.mean PANSS-P score change in the range 6.2–9.6.
For the TEA trial, we decided in our updated
sample size estimation, based on data from a
head-to-head trial comparing olanzapine vs
quetiapine in EOS [20], that it would be clinically
relevant to be able to detect a difference of 3 points
in outcome score on the PANSS-P scale between
the two drugs.
Underpowered trials bear the risk of both type 1 and
type 2 errors. On the other hand, an unnecessarily large
sample size wastes resources, from participants and
researchers and may increase risk of type 1 error, by
rejecting the null hypothesis in favor of small significant
effects that are clinically meaningless [113]. Challenges
regarding sample size calculations often, as in this trial,
stem from uncertainty concerning parameter estimates
due to limited information prior to the launch of the
trial. Deciding on the values of the parameters included
in the sample size estimation are crucial, since relatively
small changes in best estimates of variance of the out-
comes, and in choice of size of clinical relevant differences
in outcomes, power or α demands can alter the sample
size needed. Table 4 gives some examples, including
both our original and our updated sample size estimation,
and shows the effects of variation in variables on the
sample size.
Another challenge encouraging us to update our sam-
ple size estimation was the slow participant recruitment,
as also demonstrated in other RCTs in child- and adoles-
cent psychiatry [27]. Our original sample size (based on
an estimated PANSS-P SD of 7.4, a MIREDIF of 3.5 and
power of 90%) of n = 188 was expected to be recruited
during a 2 year period from mid-2010. This expectation
was based on available statistical data from the Danish
Psychiatric Central Register concerning the incidence of
first-episode psychosis in the involved geographical
areas, whereof we expected to be able to randomiseEffect size Calculations: N = 4 * (zα/2 + zβ)
2 * (SD1/MIREDIF)
2 # N
0.47 N = 42 * (7.4 / 3.5)2 188
0.27 N = 42 * (7.4 / 2.0)2 575
0.67 N = 42 * (7.4 / 5.0)2 92
0.35 N = 42 * (10.0 / 3.5)2 343
0.61 N = 42 * (5.7 / 3.5)2 111
0.47 N = 31 * (7.4 / 3.5)2 139
0.53 N = 31 * (5.7 / 3.0)2 112
ERIDIF (minimally relevant difference), SD (standard deviation) and β (risk of
be able to detect or the smaller the estimated SD of the outcome measures or
a two-sided α (risk of type I error) = 0.05 and we assumed SD1 = SD2. Effects
d sample size calculation is balanced by allowing for a larger β, expecting a
N = 2 * (SD1
2 + SD2
2) * (zα/2 + zβ)/MIREDIF
2⇒N= 4 * (zα/2 + zβ)
2 * (SD1/MIREDIF)
2.
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primarily due to administrative difficulties in implement-
ing the trial protocol in all centres. Adjustment of the
sample size during the course of a clinical trial is a poten-
tial strategy to meet such challenges. We chose to update
our sample size estimation by 1) adjusting the estimated
SD of our primary outcome measure, change in PANSS-P,
to a score of 5.7, based empirically on new relevant data
from additional studies in the field that were relatively
large and happened to report lower SDs, 2) changing the
power from 90% to the more conventionally used 80%,
and 3) lowering the MIREDIF from 3.5 to 3.0. As a result
of these adjustments our updated sample size estimation
still aims at detecting a difference between the two inter-
ventions on the primary outcome measure of a medium
effect size of around 0.5, which is considered clinically
relevant. At present, we have included all n = 112 patients
during a recruitment period of 3½ years, and the last ran-
domised patients are terminating the blinded treatment.
We believe that the updated sample size estimation is
based on as accurate variables as possible, with the same
conservative value for α, a value of SD, which is based
on the most updated empirical body of evidence, and
relevant estimates for the expected MIREDIF and effect
size. We expect one agent being superior to the other by
a score of 3 on the change in PANSS-P, which is in line
with Arango et al. [20]. If the mean SD turns out to be
higher than 5.7, we will use the statistical principles of
interim analysis [114] to control for random errors. We
will analyse the data by using the intention-to-treat princi-
ples and application of multiple imputations for missing
data as outlined above.
Additional outcomes
Apart from the primary and secondary outcomes stated
above, we will explore additional perspectives of anti-
psychotic treatment in EOP. We find that the implication
of psychosis and medication on social relations and every-
day life needs to be better understood. One study among
adolescents with mental disorders found that 62% experi-
enced stigmatization (“being treated differently”) in rela-
tionships with peers and 46% by family members [115]. In
TEA, the participants are followed up in naturalistic treat-
ment settings after conclusion of the 3-month RCT. One
year after randomisation we assess long-term health ef-
fects (same outcomes as at 12 weeks), and by means of
qualitative interview techniques [116], we assess the
patients’ perception of everyday life and of stigmatisation
associated with psychosis and antipsychotic treatment.
Another issue that lacks attention in EOP are investi-
gations of how the variation of genes coding for enzymes
involved in drug metabolism or proteins involved in
neurotransmission can influence drug response [117-119].
We will investigate how relevant gene variations areassociated with serum concentration of antipsychotics
(at week 4 and 12) and with benefits and harms of the
antipsychotic treatment.
Finally, prognostic and background factors that could
serve as moderators of outcome are assessed at baseline.
These include premorbid functioning measured by the
Premorbid Adjustment Scale (PAS) [120]; Duration of
Untreated Psychosis (DUP) measured with the Instrument
for the Assessment of Onset and Early Course of Schizo-
phrenia (IRAOS) [121]), and intelligence measured with
the Wechsler Intelligence Scale for Children (WISC-III/
WISC-IV) [122,123], or Wechsler Intelligence Scale for
adults (WAIS-III/WAIS-IV) [124,125].
Healthy controls, matched 2:1 to the randomised TEA
patients on sex, age, and parental education, are also
recruited in order to provide reference data for specific
outcomes, including somatic assessments, cognitive func-
tion, and HRQoL measures.
Strengths and limitations
The strengths of the TEA trial is the RCT design, the
central handling of randomisation procedures, the com-
prehensive blinding, and the use of intention-to-treat
analysis, all reducing the risks of bias [126,127]. The use of
validated methods to assess benefits and harms increases
the credibility of findings. The nationwide involvement of
child and adolescent health centres aims at strengthening
the generalizability of the TEA trial results.
A higher variation of the primary outcome measure
than a priori expected may limit the statistical power of
the trial. Furthermore, since sample size estimation is
based on the primary outcome measure only, the effect
sizes of differences between interventions on secondary
measures are not a priori predicted, and we may not have
enough power to conclude on all of our data. On the other
hand, important adverse effects are likely to have larger
effect sizes than the primary efficacy outcome, providing
very likely sufficient power for these comparisons.
Conclusion
The TEA trial addresses a significant gap in current
research by conducting an independent randomised
clinical trial with focus on the treatment of youth with
severe mental illness. The TEA trial is expected to pro-
vide important and currently lacking information on
the benefits and harms of two commonly prescribed,
first-line antipsychotic compounds used to treat a vulner-
able population. Results will improve our understanding
of pharmacological effects of antipsychotics and will
help guide clinical decision-making in the treatment of
children and adolescents with psychosis.
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